Chris is Vice President of Corporate Development for Medtronic, with responsibility for acquisitions, dispositions and minority investments. During 2014, Chris led the corporate development efforts for Medtronic’s $50B acquisition of Covidien as well for Medtronic’s acquisition of both Sapiens and NGC, for $200MM and $350MM respectively.Prior to 2014, Chris was CEO of Alesia Capital Services, a management consulting firm for Fortune 500 companies, including Medtronic, Goldman Sachs, Ally, Macquarie Capital and Terex. From 1995 to 2011, Chris led M&A teams within several businesses at GE Capital, closing acquisitions totaling more than $60B across 200+ transactions in the US, Canada, Europe, Asia and Latin America.